6 February 2024

NTR announces corporate PPA with Almac Group to buy energy from Murley Wind Farm, Northern Ireland

NTR announces corporate PPA with Almac Group to buy energy from Murley Wind Farm, Northern Ireland 

Commercial operation is expected to be achieved in the second half of this year

Dublin, 6th February 2024: 

NTR, a leading sustainable infrastructure investor and asset manager, is pleased to announce that the Murley Wind Farm has entered into a corporate power purchase agreement with Almac Group, a global leader in providing a range of expert services and support across the drug development lifecycle, headquartered in Craigavon, Northern Ireland and with operations across Ireland, including in Athlone and Dundalk.

The six-turbine project is expected to achieve commercial operation in the second half of this year when the power purchase agreement will commence, providing Almac with enough clean power to reduce carbon emissions from electricity at their Craigavon campus headquarters by 95%. Almac’s Craigavon campus has undergone significant expansion in recent years with Almac announcing hundreds of £millions of investment in 2022. The campus currently employs over 4,000 of Almac’s 7,000 global workforce.

The corporate power purchase agreement market is relatively nascent in Northern Ireland and the timing of operations and the scale of the output from Murley, a 21.6MW wind farm located in Co. Tyrone, will allow Almac to significantly reduce carbon emissions from the electricity they consume making it an attractive proposition for the Group.

Murley wind farm was acquired by the NTR Renewable Energy Income Fund II in 2022 and construction of the project is significantly advanced. The Fund has invested in onshore wind, solar and battery energy storage projects across six European countries. The operating assets in this Fund produces enough clean energy to power c. 180,000 homes annually further driving Europe’s clean energy transition.

Francisco Del Rio, Associate Director of Power Sales at NTR, said: 

“We’re hugely excited to be partnering with Almac, an innovative pharmaceutical business based in Northern Ireland, on this long term corporate power purchase agreement. Corporate Such agreements play a critical role in not only supporting business’ sustainability goals but having a wider impact on driving the clean energy transition across Northern Ireland and the rest of Europe.”

Niall Harkin, Executive Director, Almac Group, said:

“We are delighted to partner with NTR on this exciting project which will allow us to power the operations at our Craigavon site with fully certified renewable energy. Almac’s participation in this project is a crucial step on our journey to net zero and will significantly reduce carbon emissions from the electricity we consume.” 

A&L Goodbody acted as legal advisors to NTR on the corporate power purchase agreement and Rabobank is the financing partner on Murley Wind Farm.

Almac was advised by E&Y Dublin on the commercial side of the Power Purchase Agreement and by Pinsent Masons Belfast on the legal side.


Further information: 

NTR Media Queries:

Gilly Lock/ Louisa Henry –

Almac Media Queries: 

Julie Watts –

Angeliki Lumpkin –

About NTR

Established in 1978, NTR is an experienced sustainable infrastructure investor and asset manager driving Europe’s clean energy transition. NTR develops, constructs and operates renewable energy projects in over 60 locations across seven European countries, specialising in wind, solar and energy storage. With approximately €1.6 billion of capital deployed, NTR has developed, constructed and operated close to 3GW of wind, solar and energy storage projects to date.

NTR’s mission of developing, constructing, and operating sustainable infrastructure in a responsible manner means that we incorporate an ESG mindset into every stage of the business. From initial investment assessment through to operational projects, NTR aims to have a positive impact on the environment and society while maintaining strong governance and risk management oversight.

For more information please visit:

About Almac 

The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Its innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, analytical services, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.

The international company is a privately owned organisation which has grown organically, now employing 7,000 highly skilled personnel across 18 facilities including Europe, the USA and Asia.

Related news & stories

All news and stories